Advertisement

Topics

"ADMA Biologics Reports Year 2016 Financial Results Accomplishments" Drugs and Medication Database

04:12 EST 19th February 2019 | BioPortfolio

Here are the most relevant "ADMA Biologics Reports Year 2016 Financial Results Accomplishments" Drugs and Medications that we have found in our database.

More Information about "ADMA Biologics Reports Year 2016 Financial Results Accomplishments" on BioPortfolio

We have published hundreds of ADMA Biologics Reports Year 2016 Financial Results Accomplishments news stories on BioPortfolio along with dozens of ADMA Biologics Reports Year 2016 Financial Results Accomplishments Clinical Trials and PubMed Articles about ADMA Biologics Reports Year 2016 Financial Results Accomplishments for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ADMA Biologics Reports Year 2016 Financial Results Accomplishments Companies in our database. You can also find out about relevant ADMA Biologics Reports Year 2016 Financial Results Accomplishments Drugs and Medications on this site too.

Showing "ADMA Biologics Reports Year 2016 Financial Results Accomplishments" Drugs and Medications, all 11

Possibly Relevant

Ultram [northwind pharmaceuticals]

NA

Atryn [revo bioloigics, inc.]

These highlights do not include all the information needed to use ATryn safely and effectively. See full prescribing information for ATryn. ATryn, Antithrombin (Recombinant) Lyophilized powder for reconstitution Initial U.S. Approval: 2009

Anticoagulant citrate dextrose a [citra labs]

ACD-A Anticoagulant Citrate Dextrose Solution, Solution A, U.S.P., PN 9350, 30 mL NDC 23731-6051-3

Levofloxacin [redpharm drug, inc.]

NA

Rejuvesol [citra labs llc]

rejuvesol red blood cell processing solution

Eucrisa [pfizer laboratories div pfizer inc]

These highlights do not include all the information needed to use EUCRISA safely and effectively. See full prescribing information for EUCRISA. EUCRISA™ (crisaborole) ointment, 2%, for topical useInitial U.S. Approval: 2016

Meloxicam [redpharm drug, inc.]

NA

Isopto atropine [alcon laboratories, inc.]

These highlights do not include all the information needed to use ISOPTO® ATROPINE safely and effectively. See full prescribing information for ISOPTO® ATROPINE ISOPTO® ATROPINE (atropine sulfate ophthalmic solution) 1%, for topical  ophthalmic useIni

Tetracaine hydrochloride [alcon laboratories, inc.]

These highlights do not include all the information needed to use Tetracaine Hydrochloride Ophthalmic Solution 0.5% STERI‑UNITsafely and effectively. See full prescribing information for Tetracaine Hydrochloride Ophthalmic Solution. Tetracaine Hydrochlo

Inflectra [pfizer laboratories div pfizer inc]

These highlights do not include all the information needed to use INFLECTRA safely and effectively. See full prescribing information for INFLECTRA. INFLECTRA (infliximab-dyyb) Lyophilized Concentrate for Injection, for Intravenous Use Initial U.S. Approva

Nitrous oxide [praxair mexico, s. de r.l. de c.v]

NA



Advertisement
Quick Search
Advertisement
Advertisement